Anti-TTL11/ TTLL11/ C9orf20 functional antibody
Anti-TTL11/ TTLL11/ C9orf20 functional antibody for cell culture, ELISA & in-vivo assay
Go to TTLL11/TTLL11 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE1613-Ab-1/ GM-Tg-hg-SE1613-Ab-2 | Anti-Human TTLL11 monoclonal antibody | Human |
GM-Tg-rg-SE1613-Ab-1/ GM-Tg-rg-SE1613-Ab-2 | Anti-Rat TTLL11 monoclonal antibody | Rat |
GM-Tg-mg-SE1613-Ab-1/ GM-Tg-mg-SE1613-Ab-2 | Anti-Mouse TTLL11 monoclonal antibody | Mouse |
GM-Tg-cynog-SE1613-Ab-1/ GM-Tg-cynog-SE1613-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TTLL11 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE1613-Ab-1/ GM-Tg-felg-SE1613-Ab-2 | Anti-Feline TTLL11 monoclonal antibody | Feline |
GM-Tg-cang-SE1613-Ab-1/ GM-Tg-cang-SE1613-Ab-2 | Anti-Canine TTLL11 monoclonal antibody | Canine |
GM-Tg-bovg-SE1613-Ab-1/ GM-Tg-bovg-SE1613-Ab-2 | Anti-Bovine TTLL11 monoclonal antibody | Bovine |
GM-Tg-equg-SE1613-Ab-1/ GM-Tg-equg-SE1613-Ab-2 | Anti-Equine TTLL11 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE1613-Ab-1/ GM-Tg-hg-SE1613-Ab-2; GM-Tg-rg-SE1613-Ab-1/ GM-Tg-rg-SE1613-Ab-2; GM-Tg-mg-SE1613-Ab-1/ GM-Tg-mg-SE1613-Ab-2; GM-Tg-cynog-SE1613-Ab-1/ GM-Tg-cynog-SE1613-Ab-2; GM-Tg-felg-SE1613-Ab-1/ GM-Tg-felg-SE1613-Ab-2; GM-Tg-cang-SE1613-Ab-1/ GM-Tg-cang-SE1613-Ab-2; GM-Tg-bovg-SE1613-Ab-1/ GM-Tg-bovg-SE1613-Ab-2; GM-Tg-equg-SE1613-Ab-1/ GM-Tg-equg-SE1613-Ab-2 |
Products Name | Anti-TTLL11 monoclonal antibody |
Format | mab |
Target Name | TTLL11 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-TTLL11 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE1613-Ag-1 | Recombinant multi-species TTL11/ TTLL11/ C9orf20 protein |
Target information
Target ID | GM-SE1613 |
Target Name | TTLL11 |
Gene ID | 158135,74410,689746,698836,491355,101094458,613902,100071668 |
Gene Symbol and Synonyms | 4932702F08Rik,4933424A20Rik,bA244O19.1,C9orf148,C9orf20,D2Ertd624e,TTLL11,TTLL11-IT1 |
Uniprot Accession | Q8NHH1 |
Uniprot Entry Name | TTL11_HUMAN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000175764 |
Target Classification | N/A |
The target: TTLL11, gene name: TTLL11, also named as C9orf20, bA244O19.1. Predicted to enable tubulin binding activity and tubulin-glutamic acid ligase activity. Predicted to be involved in microtubule cytoskeleton organization and protein polyglutamylation. Predicted to act upstream of or within microtubule severing. Predicted to be located in cytosol. Predicted to be active in cilium. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.